Influenza virus vaccine live intranasal - MedImmune vaccines. CAIV-T, influenza vaccine live intranasal

Drugs in R and D

Volumn 4, Issue 5, 2003, Pages 312-319

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSTIMULATING AGENT; INFLUENZA VACCINE; LIVE VACCINE; NOSE SPRAY; PLACEBO;

ACTIVE IMMUNIZATION; AEROSOL; AGE; ANTIGENICITY; ARTICLE; ASTHMA; BIOEQUIVALENCE; BODY TEMPERATURE; CHILL; CLINICAL STUDY; CLINICAL TRIAL; COLD ACCLIMATIZATION; CONTRACT; CONTROLLED CLINICAL TRIAL; COUGHING; CRYOPRESERVATION; DISEASE EXACERBATION; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG INDUSTRY; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; FEVER; FOOD AND DRUG ADMINISTRATION; GENETIC REASSORTMENT; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INTRANASAL DRUG ADMINISTRATION; LICENCE; LIQUID; NASOPHARYNX; NONHUMAN; ORTHOMYXOVIRUS; PATENT; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEASONAL VARIATION; SORE THROAT; TEMPERATURE SENSITIVITY; UNITED STATES; VACCINATION; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN; WHEEZING;

EID: 0141818232     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200304050-00007     Document Type: Article

References (10)

1. MedImmune Inc. FDA Approves FluMist™ First Nasal Mist Influenza Vaccine Licensed in the US. Media Release: 17 Jun 2003. Available from URL: http://www.medimmune.com
2. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. Journal of the American Medical Association 282: 137-144, 14 Jul 1999
3. Jackson LA, Holmes SJ, Mendelman PM. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist™, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17: 1905-1909, 9 Apr 1999
4. Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110: 662-672, Oct 2002
5. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18: 899-906, 10 Dec 1999
6. Longini Jr IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine 18: 1902-1909, 17 Mar 2000
7. Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. Journal of Pediatrics 136: 168-175, Feb 2000
8. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. New England Journal of Medicine 338: 1405-1412, 14 May 1998
9. Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. Journal of Infectious Diseases 181: 1133-1137, Mar 2000
10. Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatric Infectious Disease Journal 20: 740-746, Aug 2001